Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04362501 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

A Phase 2 study of Chronic Sinusitis, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
33
Enrollment target
1
Study location

NCT04362501: Completed Phase 2 study of Chronic Sinusitis, sponsored by Johns Hopkins University.

NCT04362501 is a Phase 2 study of Chronic Sinusitis that has completed, run by Johns Hopkins University. The registered enrollment target is 33 participants, below the 192-participant average among 9 other Chronic Sinusitis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04362501, a Phase 2 study of Chronic Sinusitis, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has previously been determined. The additional information gained from secondary and exploratory outcomes will help provide important insight for applied research studies and may also provide practical guidance to clinicians on how to select patients for treatment.

Primary Outcome

Sino-Nasal Outcome Test (SNOT-22) survey score after six months treatment (range 0-110). Higher score means worse symptoms.

Conditions Studied

Interventions

  • DRUG placebo
  • BIOLOGICAL dupilumab

Study Locations (1)

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2020-10-15
Est. Completion 2025-09-30
Phase Phase 2
Johns Hopkins University

1,448 total trials

What the finished NCT04362501 record still lists

NCT04362501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 192-participant average among 9 other Chronic Sinusitis trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Chronic Sinusitis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT04362501 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT04362501 about?

NCT04362501 is a clinical study titled "Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)". The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has previously been determined. The additional information gained from seconda...

What is the current status of trial NCT04362501?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2020-10-15. Estimated completion is 2025-09-30.

What conditions does trial NCT04362501 study?

This clinical trial studies the following conditions: Chronic Sinusitis.

What interventions are being tested in trial NCT04362501?

The interventions under investigation include: placebo (DRUG), dupilumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04362501?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04362501 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Sinusitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04362501's enrollment target sits among peer trials

33 6th of 9 higher than 4 of 9 other Chronic Sinusitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Sinusitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04362501, the US trial registry maintained by the National Library of Medicine. NCT04362501 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.